Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial. (8th June 2015) - Ozelo, M.; Misgav, M.; Abdul Karim, F.; Lentz, S. R.; Martin‐Salces, M.; Matytsina, I.; Saugstrup, T.; Santagostino, E.